3626 results for «318»
3626 results
Tailored transfemoral TAVI in complex anatomies - LIVE Case
11 Sep 2025 – From PCR Rio Valves 2025
Supported by an unrestricted educational grant from Medtronic
An 89-year-old male with hypertension, dyslipidemia, current smoking, stage III kidney disease, and a history of diagonal PCI in 2010 presented with severe symptomatic aortic stenosis and a small annulus (410 mm²), with RBBB on ECG.
Via bilateral femoral access,...
The role of mitral TEER in advanced heart failure
11 Sep 2025 – From PCR Rio Valves 2025
This session delves into the role of mitral transcatheter edge-to-edge repair (TEER) in advanced heart failure patients. Understand the indications for mitral TEER in severe left ventricular dysfunction, prognostic challenges in heart failure with severe mitral regurgitation, and review therapeutic alternatives including the pathway from TEER...
Redo TAVI
12 Sep 2025 – From PCR Rio Valves 2025
This session focuses on the challenges and strategies of redo TAVI, from careful planning to valve selection and tailored procedural approaches. Learn how to manage different valve platforms, optimise outcomes in valve-in-valve scenarios, and prevent complications such as coronary obstruction through real case discussions.
The impact of COVID-19 pandemic on interventional cardiologists in training
23 Oct 2020
In collaboration with EuroIntervention Journal
The authors decided to create a survey tailored for ICTs in order to assess the changes in their training. Capturing the essence of the responses may help to identify the most appropriate strategies to provide the highest standards and skills achievements in COVID-19...
TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation
04 Nov 2024
Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.
Also watch the interview with Susheel K. Kodali

Author
Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial
07 Apr 2024
REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.
Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Author

Author